WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Wednesday, September 12, 2018

Sensor-Based Gait Analysis Can Enhance Individualized Evaluation of Parkinson’s Patients, Study Suggests

SEPTEMBER 12, 2018 BY ALICE MELÃO IN NEWS.


Use of sensor-based methods to evaluate gait can improve individual assessments of Parkinson’s disease patients who are undergoing dopaminergic treatment, researchers suggest.
Gait impairment as a consequence of Parkinson’s disease progression can drastically reduce patients’ quality of life. However, available strategies to evaluate gait alterations for individual patient care are still limited.
More recently, the development of mobile sensor-based gait analysis methods has enabled the objective assessment of gait deficits in Parkinson’s patients. Still, the applicability and effectiveness as an individualized evaluation approach has not been established.
A team led by researchers at FAU Erlangen-Nürnberg in Germany compared gait outcomes measured with standard and sensor-based methods in Parkinson’s patients undergoing dopamine replacement therapy.
The study enrolled 13 patients who had mean disease duration of about 15 years and were receiving a mean levodopa equivalent daily dose of 1,077 mg.
All participants started treatment with Apokyn (apomorphine) according to standard protocol, by injecting a defined dose subcutaneously (under the skin) every 15 minutes until achieving the best motor response. Apokyn is an injectable agent usually used to restore body movement control between doses of levodopa, during “off” periods — periods when medication wears off and symptoms reappear.
To track gait movement, researchers used sensors (3D-acceerometers and 3D-gyroscopes) attached to the shoes that could detect small changes in movement orientation and speed. These sensors measure parameters such as rotation and dynamic acceleration resulting from motion, shock or vibration, and can measure tremor in these patients.
After treatment with Apokyn, patients showed a significant improvement in gait movement, as shown by increase in certain gait parameters, including stride speed and length, maximum toe clearance, gait velocity, swing time, heel strike angle, and toe-off angle.
To better evaluate the potential of sensor-based gait analysis to perform individualized evaluations, researchers compared the data obtain between Apokyn administrations within in each patient.
This strategy allowed them to confirm that sensor-based results could effectively measure small gait differences resulting from Apokyn dosages. It could discriminate significant improvements in stride speed, length, and time, and maximum toe clearance between two sequential administrations, as well as detect when no additional improvements were achieved with higher doses.
To validate these findings, researchers compared the sensor-based data with motor scores collected with the standard measure Unified Parkinson Disease Rating Scale (UPDRS) (a 50-question assessment of both motor and non-motor symptoms associated with Parkinson’s).
Improvement in gait parameters (obtained using sensor-based gait analysis) between Apokyn injections reflected improvement in patients’ overall motor performance as measured by the UPDRS, in particular in items related to postural stability and gait.
“[S]ensor-based gait analysis provides objective target outcome measure of gait performance, reflecting apomorphine-induced improvement of motor performance in [Parkinson’s disease],” researchers wrote.
“We show that using instrumented gait analysis to measure individual changes in gait parameters … may be a powerful assessment strategy for routine clinical care in individual [Parkinson’s disease] patients,” they concluded.
However, the authors caution that additional studies in larger groups of patients are still warranted to further validate the applicability and implementation of sensor-based gait analysis as an objective and individualized diagnostic tool for real-life healthcare.
https://parkinsonsnewstoday.com/2018/09/12/sensor-based-gait-analysis-can-enhance-evaluation-of-parkinsons-patients/

No comments:

Post a Comment